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ChondrocyteFibroblast growth factors (FGFs) and their receptors (FGFRs) play signiﬁcant roles in vertebrate organogenesis
and morphogenesis. FGFR3 is a negative regulator of chondrogenesis and multiple mutations with constitutive
activity of FGFR3 result in achondroplasia, one of the most common dwarﬁsms in humans, but the molecular
mechanism remains elusive. In this study, we found that chondrocyte-speciﬁc deletion of BMP type I receptor
a (Bmpr1a) rescued the bone overgrowth phenotype observed in Fgfr3 deﬁcient mice by reducing chondrocyte
differentiation. Consistently, using in vitro chondrogenic differentiation assay system, we demonstrated that
FGFR3 inhibited BMPR1a-mediated chondrogenic differentiation. Furthermore, we showed that FGFR3 hyper-
activation resulted in impaired BMP signaling in chondrocytes of mouse growth plates. We also found that
FGFR3 inhibited BMP-2- or constitutively activated BMPR1-induced phosphorylation of Smads through a mech-
anism independent of its tyrosine kinase activity. We found that FGFR3 facilitates BMPR1a to degradation
through Smurf1-mediated ubiquitination pathway. We demonstrated that down-regulation of BMP signaling
by BMPR1 inhibitor dorsomorphin led to the retardation of chondrogenic differentiation, whichmimics the effect
of FGF-2 on chondrocytes and BMP-2 treatment partially rescued the retarded growth of cultured bone rudi-
ments from thanatophoric dysplasia type II mice. Our ﬁndings reveal that FGFR3 promotes the degradation of
BMPR1a, which plays an important role in the pathogenesis of FGFR3-related skeletal dysplasia.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Fibroblast growth factors (FGFs) and their receptors (FGFRs) play
essential roles in vertebrate organogenesis and morphogenesis by con-
trolling cell proliferation, differentiation, migration, and apoptosis.
Germline activation mutations of ﬁbroblast growth factor receptor 3
(FGFR3) are responsible for achondroplasia (ACH) and several other
types of chondrodysplasia including hypochondroplasia (HCH) and
thanatophoric dysplasia (TD) [1–4]. Several groups have demonstrated
that activation of FGFR3 inhibits chondrocyte proliferation and blockslinchen70@163.com (L. Chen).its differentiation andmatrix synthesis [5–14],which is thought to be re-
sponsible for the development of achondroplasia and chondrodysplasia.
The skeletal development is precisely regulated by the integrated effects
of diverse signaling pathways [15–17] and dysregulation of these signal-
ing pathways can lead to a variety of skeletal dysplasia [18–20]. Current-
ly, many signaling pathways including IGF, BMP, PTH,Wnt and Ihh have
been also identiﬁed in regulation of endochondral ossiﬁcation during
the development of achondroplasia [20–24].
BMPs are members of the transforming growth factor-β (TGF-β) su-
perfamily. BMPs trigger cellular responses through canonical (Smad)
and noncanonical (non-Smad) pathways [25–28]. Smad ubiquitylation
regulatory factor 1 (Smurf1) and Smurf2 are members of the Nedd4
(neural precursor cell-expressed developmentally downregulated
gene 4) family and are key negative regulators of TGF-β/BMP signaling
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and BMPR1a, causing their ubiquitination and subsequent proteosomal
degradation [30,31]. Accumulating evidence suggests that BMP/BMPR1
signaling is indispensable in regulation of chondrogenesis and endo-
chondral ossiﬁcation [21,32–37]. Conventional knockout of Bmpr1a
leads to embryonic lethality [38] and cartilage-speciﬁc Bmpr1a null
mice (Bmpr1a-cKO) shows a mild generalized chondrodysplasia with
shortened long bones and delayed endochondral ossiﬁcation, as well
as smaller and ﬂattened rib cages, which leads to distressed respiratory
function and subsequent post-natal death [21].
Interestingly, both Bmpr1a-cKO and Fgfr3K644E germline activated
mutant mice (mimicking human TDII) have chondrodysplasia and
early post-natal death phenotype resulting from under-developed rib
cages [21,39]. These observations support the notion that BMP and
FGFR3 pathways are antagonistic in the regulation of chondrogenesis
and endochondral development. It has been demonstrated that mice
mimicking human ACH had decreased BMP-4 expression in post-natal
growth plates [24], and the retarded development of the cultured em-
bryonic limbs of ACH mice could be rescued by addition of BMP-2
[40]. These studies implied that BMP and FGFR3 signaling pathways
might cross talk in regulation of chondrogenesis and development of
achondroplasia.
A number of studies reported that FGF and BMP signaling interplay
during the development ofmultiple cell lineages and tissues [41–43]. Ac-
tivated MAP kinase cascades, especially ERK1/2 MAPK, as an important
downstream pathway of FGFs/FGFRs signaling, can phosphorylate the
linker region of Smad1/5, which not only causes Smurf1-dependent
ubiquitination and degradation of the Smads, but also prevents
Smad1/5 from translocation into the nucleus by inhibiting their interac-
tion with the nuclear pore complex protein Nup214 [44]. However, the
crosstalk between BMP and FGFR3 in chondrogenesis and achondropla-
sia remains unknown.
In this study, we report that FGFR3 antagonizes the BMP signaling
during chondrogenesis and development of achondroplasia. We pro-
pose that FGFR3 inhibits chondrocyte differentiation by triggering
Smurf1-mediated BMPR1 degradation, which may play an essential
role in the pathogenesis of FGFR3-related skeletal dysplasia.
2. Materials and methods
2.1. Mice
Fgfr3G369C/+ mice (ACH) [7], Fgfr3 knockout mice (Fgfr3−/−) [6],
Fgfr3+/K644Eneo mice [39], Bmpr1aﬂox/ﬂox mice [45] and EIIa-Cre mice
[46], Col2a1-Cre [47] were reported previously. Animals were handled
in accordance with guidelines approved by the Institutional Animal
Care and Use Committee of Daping Hospital, Third Military Medical
University.
2.2. Skeletal preparation and histology
Skeletal preparations were performed as we previously described
[48]. Brieﬂy, mice were eviscerated and ﬁxed in 95% EtOH at 4 °C over-
night, followed by Alcian blue staining (30 mg/100 ml in 80% EtOH) at
room temperature. Samples were stained in Alizarin red (5 mg/100 ml
in 0.5% KOH) and cleared in a series of graded KOH in glycerol. For histol-
ogy, samples were ﬁxed in 4% paraformaldehyde, decalciﬁed and em-
bedded in parafﬁn. Parafﬁn sections (4–6 μm) were cut for histological
analysis.
2.3. Primary chondrocyte culture
Primary chondrocytes were isolated from cartilage of knee joints of
5 day old mice. Brieﬂy, dissected tissues with cartilage were ﬁrst
digested with 0.25% trypsinase/DMEM at 37 °C for 15 min to remove
muscles, ligaments and bone tissues. Chondrocytes were isolated fromthe knee joints by further digesting with 0.1% collagenase II/DMEM for
overnight in a CO2 incubator at 37 °C. Cells were plated in 12-well
plates at a density of 1×105 cells/cm2, cultured inDMEM/F12 (1:1)me-
dium supplemented with penicillin/streptomycin and 10% FBS until
reaching sub-conﬂuence.
2.4. Plasmids and cell lines
Full length mouse FGFR3 cDNA was cloned from SK-R3 and inserted
into the pcDNA3.1/Myc vector (Clontech, USA) (Myc-FGFR3).Wild-type
andY373C, K650MandK508M-FGFR3with ﬂag-tagwere kindly provid-
ed by Pavel Krejci (Masaryk University, Czech Republic) [49]. Myc-
Smurf1 and Flag-Smurf1 (C699A) plasmids were provided by Lingqiang
Zhang [50] (Beijing Institute of RadiationMedicine, China). HA-BMPR1a,
HA-BMPR1b, caBMPR1b and GCCG-Luc plasmids were provided by
Yeguang Chen (Tsinghua University, China). HA-caBMPR1a (Q227D)
was a gift from Dr. Imamura (Cancer Institute-JFCR, Department of Bio-
chemistry). pFR-Luc and pFA-ELK1 plasmids were purchased from
Clontech.
HEK293T, HepG2, NIH3T3, HeLa and C3H10T1/2 cells were cultured
in DMEM supplementedwith 10% FBS. ATDC5were cultured in DMEM/
F12 (1:1) supplemented with 5% FBS. All the cells were kept at 37 °C in
5% CO2-containing atmosphere. The medium and serum were pur-
chased from Hyclone.
2.5. Reagents and antibodies
FGF-2 and BMP-2 were purchased from R&D Systems, chloroquine
and PD173074were fromSigma.MG132was obtained fromCalbiochem.
Antibodies were from various sources, including Anti-Actin (AC-15) and
Anti-Flag M2 from Sigma, anti-Myc (9E10), anti-HA (F-7), anti-GFP (FL),
anti-FGFR3, anti-BMPR1b, and anti-PCNA from Santa Cruz, anti-
pSmad1/5, anti-Smad1, and anti-Smad5 from Cell Signal Corporation,
anti-Smurf1 antibody was from Invitrogen and anti-BMPR1a antibody
from R&D Systems. Anti-pSmad1S214 was kindly provided by Eddy De
Robertis [51].
2.6. Western blot analysis
Cells were lysed in an ice-cold buffer containing 50 mM Tris–HCl
(pH 7.4), 150mMNaCl, 1%Nonidet P-40, 0.1% SDS, and a cocktail of pro-
tease inhibitors (Roche). Protein samples (10 μg) were resolved on a
10% or 12% SDS-PAGE gel and transferred onto a PVDF membrane
(Millipore). Then indicated antibodies were used to probe the blots
followed by ECL signal detection (Pierce).
2.7. Co-immunoprecipitation
HEK293T cells were plated in 60 mm dishes the day before transfec-
tion. Myc-Smurf1 and HA-BMPR1a (or other plasmids as indicated)
were transfected individually or together. pcDNA3.1/Myc empty vector
was added to balance the equal transfection efﬁciency. After transfection
for 24–36 h, cells were harvested and lysed in 600 μl TNN buffer (50mM
TrisCl, 150 mM NaCl, 50 mM NaF, 0.5% NP-40, pH7.5) with protease in-
hibitors to prepare whole-cell lysates. Samples were centrifuged at 4 °C
at top speed to isolate the supernatant, 500 μl lysate was mixed with in-
dicated antibodies and incubated at 4 °C for 1–2 h, followed by addition
of protein G or A-agarose beads to pellet the immune complex. The
immunoprecipitants and5%of lysateswere analyzed by immunoblotting.
For endogenous coimmunoprecipitations, the whole lysates of
HepG2 or siRNA-transfected HeLa cells were extracted. Aliquots were
taken as lysate samples, and the remainderswere subjected to immuno-
precipitation with an antiserum against Smurf1 or with a preimmune
serum (IgG) control. Puriﬁed immune complexes were probed for
BMPR1a (or Smurf1, FGFR3) by immunoblotting.
Fig. 1. Deletion of Bmpr1a in chondrocytes rescues the phenotypes of Fgfr3−/− mice by
inhibiting chondrocyte differentiation. a,b. Deletion of Bmpr1a in chondrocytes rescued
the bone overgrowth phenotype of Fgfr3 deletionmice. Side views (a) and the X-ray anal-
ysis (b) of the 30-day old mice. A: Bmpr1aﬂox/ﬂox;Fgfr3−/−, B: Bmpr1aﬂox/ﬂox;Fgfr3+/−,
C: Bmpr1a-cKO;Fgfr3−/−. Note that Bmpr1a-cKO;FGFR3+/+ and Bmpr1a-cKO;FGFR3+/−
mice were lethal after birth. c. Fgfr3 deletion results in increased width of hypertrophic
zone but double deletion of Bmpr1a and Fgfr3 narrows the zone of hypertrophic
chondrocytes. Alcian blue/alizarin red staining of proximal tibia growth plates of 1 day
old indicatedmice. (d) Quantitative analysis of length of the chondrocyte zones in growth
plates (n = 3, two-way ANOVA, *p b 0.05, **p b 0.01, ***p b 0.001). R: resting zones,
P: proliferation zones, PH: prehypertrophic zones; H: hypertrophic zones, black arrow in-
dicates the proliferative columns.
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NIH3T3 cells were plated in 24-well plates the day before transfec-
tion. 0.1 μg reporter plasmid (BRE-Luc, GCCG-Luc, pFR-Luc) together
with 5 ng internal control plasmid (pRL-TK) was transfected each
well. Constructs expressing HA-caBMPR1a, pcDNA3.1/Myc-FGFR3,
Flag-FGFR3 or its mutants or empty vector were co-transfected as indi-
cated, 1.0 μg each per well. 24–36 h after transfection, the reporter gene
activity was assayed using the Dual Luciferase Assay System (E1910;
Promega). For inhibitor assay, the transfected cells were treated by dif-
ferent inhibitors for 6 h before collecting the cells or as indicated.
2.9. Real-time RT-PCR
Total RNA was isolated by TRIzol reagent (Invitrogen) according to
the manufacturer's instructions. All reactions were performed in
Mx3000P PCR machine (Stratagene) using the Two-Step QuantiTect
SYBR Green RT-PCR Kit (Takara) and reaction conditions were opti-
mized for each of the genes by changing the annealing temperature.
Each run consisted of samples for genes of interest and cyclophilin A.
The primers used were as follows: cyclophilin A (5′-CGAGCTCTGAGC
ACTGGAGA-3′ and 5′-TGGCGTGTAAAGTCACCACC-3′), Id-1 (5′-AGGT
GAACGTCCTGCTCTAC-3′ and 5′-GTCCCGACTTCAGACTCCG-3′), Id-2
(5′-CGGTGAGGTCCGTTAGGAAAA-3′ and 5′-CATGTTGTAGAGCAGACT
CATCG-3′), Id-3 (5′-CGACCGAGGAGCCTCTTAG-3′ and 5′-GCAGGATT
TCCACCTGGCTA-3′), Ihh (5′-CAATCCCGACATCATCTTCA-3′and 5′-
GCGGCCCTCATAGTGTAAAG-3′), Collagen II (5′-CTGGTGGAGCAGCAAG
AGCAA-3′ and 5′-CAGTGGACAGTAGACGGAGGAAAG-3′), Sox9 (5′-
TTCCTCCTCCCGGCATGAGTG-3′ and 5′-CAACTTTGCCAGCTTGCACG-3′),
Col10 (5′-GCAGCATTACGACCCAAGAT-3′ and 5′-CATGATTGCACTCCCT
GAAG-3′), Mmp13 (5′-CAGTTGACAGGCTCCGAGAA-3′ and 5′-CGTGTG
CCAGAAGACCAGAA-3′). BMPR1a (5′-TCATGTTCAAGGGCAGAATCTA
GA-3′ and 5′-GGCAAGGTATCCTCTGGTGCTA-3′), BMPR1b (5′-CCTCGG
CCCAAGATCCTAC-3′ and 5′-CCTAGACATCCAGAGGTGACA-3′).
2.10. In vitro culture of metatarsal rudiment
Metatarsal rudiments were isolated from 18.5 pc pregnant female
mice. Three to ﬁve left–right paired central bones were used in experi-
ments. Rudiments were cultured in 24-well plates with 350 ml BGJb
medium supplemented with 0.05 mg/ml ascorbic acid, 0.5 mg/ml
L-glutamine, 10 mg/ml streptomycin, 10 units/ml penicillin, 1 mM
β-glycerophosphate and 0.2% BSA (fraction V). Explants were grown
at 37 °C in a humidiﬁed 5% CO2 incubator. FGF-2 (20 ng/ml) or
dorsomorphin (10 μM) was added to cultures 16–20 h after dissection.
Mediumwas changed on the secondday of culture. The rudimentswere
observed and photographed under a dissecting microscope (Leica) at 0
and 4 or 7 d of treatment. The total, mineralization, hypertrophic and
proliferation length of metatarsal rudiments were measured as de-
scribed previously [52] with an eyepiece scale. Changes of bone length
were expressed as percentage increase relative to the value before the
treatment (percentage increase = length at day− length at day 0] /
length at day 0). Data are expressed asmean± SD, and the signiﬁcance
of differences was evaluated with Student's t test.
2.11. Transfection of C3H10T1/2 and ATDC5 cells and chondrogenic
differentiation assay
C3H10T1/2 cells were transfected using Lipofectamine 2000
(Invitrogen) following the manufacturer's instructions. The transfected
cells were trypsinized, inoculated as micromass, and induced for chon-
drogenesis by applying recombinant BMP-2 (300 ng/ml). At the time
point of 3 and 7 days, mRNA was collected for real-time RT-PCR analy-
ses for chondrogenic differentiation marker genes.
ATDC5 cells were transfected with indicated plasmids. To induce
chondrogenesis, cells were cultured in the medium supplementedwith 10 μg/ml human insulin. The medium was replaced every
2–3 days. At the time point of 3 and 7 days, mRNA was collected for
real-time RT-PCR analyses.
2.12. Immunohistochemistry
Skeletal preparations were immunostained using SP-9000
Histostain-Plus kits from Beijing Zhongshan Biotechnologies. Mice
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decalciﬁed in 15% EDTA (pH 7.4) and embedded in parafﬁn; parafﬁn
sections (4–6 μm) were cut for histological analysis. Sections were
pretreated with 0.1% trypsin for antigen demasking. Sections were
blockedwith 5% goat serum, incubatedwith indicated primary antibody
overnight at 4 °C, and then incubated with the appropriate secondary
antibody at room temperature. Color was developed with diaminoben-
zidine solution and sections were counterstained with Alcian blue.
2.13. RNAi protocols
The siRNA targeting Smurf1, FGFR3 and non-target control were or-
dered from Dharmacon (Thermo Fisher Scientiﬁc). HeLa cells or HepG2
was transfected with 50 nM siRNA using DharmoFect 4 (Thermo Fisher
Scientiﬁc) according to the manufacturer's instructions. 48 h later, the
total protein was extracted and the protein level was assayed by IP or
Western blotting.
2.14. Statistics
Data are presented as means ± standard deviation (SD). Data
were evaluated using an independent sample Student's t test or two-
way analysis of variance (ANOVA) test. *p b 0.05, **p b 0.01 and
***p b 0.001 were considered to be statistically signiﬁcant.
3. Results
3.1. Deletion of Bmp1a in chondrocytes rescues the phenotypes of
Fgfr3−/−mice
We and others have previously reported that Fgfr3 null mice had a
bone overgrowth phenotype resulted from enhanced endochondralFig. 2. FGFR3 inhibits BMPR1a-mediated chondrocyte differentiation. a,b. FGFR3 inhibitedBMPR
b) of chondrocyte differentiation frommesenchymal cells (n=3, two-way ANOVA, *p b 0.05, *
in the early stage (3 days, c) or later stage (7 days, d) of chondrocyte differentiation in precursbone formation [5,6].Micewith Bmpr1a deletion in chondrocytes exhib-
it defects in the growth plates and die shortly after birth as a result of re-
spiratory failure caused by generalized chondrodysplasia [21,32]. We
questioned whether the bone overgrowth phenotype of Fgfr3 deﬁcient
(Fgfr3−/−) mice is associated with BMPR1a-mediated BMP signaling.
In this study, Fgfr3−/− [6], Bmpr1aﬂox/ﬂox [45] and Col2a1-Cre [47]
mice were used to mate each other based on Cre/LoxP conditional
knockout strategy. To improve the birth rate of double knockout mice,
BMPR1aﬂox/ﬂox;Fgfr3−/− mice were mated with Bmpr1a+/ﬂox;Col2a1-
Cre;FGFR3+/− mice to generate BMPR1aﬂox/ﬂox;Col2a1-Cre;FGFR3−/−
mice (Bmpr1a-cKO;Fgfr3−/−).We found that when Bmpr1awas deleted
in the chondrocytes of Fgfr3−/−mice, themicewere able to survive into
adulthood,with a smaller skeleton and body size (Fig. 1a–b). The exam-
ination of the growth plate proliferative zones showed amarked reduc-
tion in proliferative zones in Bmpr1a-cKO;Fgfr3−/−mice compared to
Bmpr1aﬂox/ﬂox;Fgfr3−/− mice (Black arrow, Fig. 1c,d, C vs A). Long
bone growth plates displayed a wider hypertrophic (h) zone in
Bmpr1aﬂox/ﬂox;Fgfr3−/−mice compared to the Bmpr1aﬂox/ﬂox;Fgfr3+/− lit-
termates (Fig. 1c,d, A vs B). The width of the hypertrophic zone of
Bmpr1a-cKO;Fgfr3−/− mice was decreased compared to those of the
Bmpr1aﬂox/ﬂox;Fgfr3−/−mice (Fig. 1c, C vs A). Furthermore, the hypertro-
phic chondrocytes showed a smaller size and more-disorganized
columns in Bmpr1a-cKO;Fgfr3−/− mice compared to Bmpr1aﬂox/ﬂox;
Fgfr3−/−mice (Fig. 1c, C vs A). Collectively, these data showed that de-
pletion of Bmpr1a in chondrocytes rescued the boneovergrowth pheno-
type of Fgfr3 deﬁcient mice by reducing chondrocyte differentiation.
3.2. FGFR3 inhibits BMPR1a-mediated chondrocyte differentiation
To further investigate the physiological role of FGFR3-mediated inhi-
bition on BMPR1a signaling pathway in the regulation of chondrogene-
sis, we examined the effect of FGFR3 on BMPR1a-mediated chondrocyte1a induced expression of genes involved in the early stage (3 days, a) or later stage (7 days,
*p b 0.01, ***p b 0.001). c,d. FGFR3 inhibited BMPR1a induced expression of genes involved
or chondrocytes (n = 3, two-way ANOVA, *p b 0.05, **p b 0.01, ***p b 0.001).
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ture mesenchymal C3H10T1/2 and precursor chondrocyte ATDC5 cell
line was used as model of chondrogenesis in the early and later stages
of endochondral bone development [53]. The Real-time PCR results
showed that transient transfection of FGFR3 resulted not only in the in-
hibition of the expressions of marker genes Col2, Sox9 and Comp in-
volved in the early stage (3 days, Fig. 2a), but also in the inhibition of
expressions of marker genes Col10 and Mmp13 involved in the later
stage (7 days, Fig. 2b) of chondrocyte differentiation from immature
mesenchymal C3H10T1/2 cells (Fig. 2a, b). Furthermore, FGFR3 also
inhibited BMPR1a induced expression of genes involved in the early
stage (3 days, Fig. 2c) or later stage (7 days, Fig. 2d) of chondrocyte dif-
ferentiation in precursor chondrocyte ATDC5 (Fig. 2c,d). These data
demonstrated that FGFR3 inhibited BMPR1a-mediated chondrocyte dif-
ferentiation. Collectively, the in vivo and in vitro data suggest that
FGFR3 inhibits BMPR1a-mediated signaling to regulate chondrocyte
differentiation.Fig. 3. FGFR3 inhibits BMP signaling in growth plate chondrocytes of mice. a. Western blot re
littermates stimulated with BMP-2 (25 ng/ml) for 45 min. The band signal intensity was quan
(n = 3, two-way ANOVA, *p b 0.05, **p b 0.01). b. Immunohistochemistry analysis results of B
Bmpr1a-cKO;Fgfr3−/−mice. The percentage of the BMPR1 positive cells in the prehypertrophi
A: Bmpr1aﬂox/ﬂox;Fgfr3−/−, B: Bmpr1aﬂox/ﬂox;Fgfr3+/−, C: Bmpr1a-cKO;Fgfr3−/−. c. Real-time PC
type mice. d. Western blot results of BMPR1a, 1b and pSmad1/5 in the primary chondrocytes
band signal intensity in Fig. 3d (n = 3, Student's t-test, *p b 0.05, **p b 0.01, ***p b 0.001). f.
wild-type mice for BMP signaling target genes Id-1, Id-2, Id-3 and Ihh (n = 3, Student's t-test,3.3. FGFR3 inhibits BMP signaling in the chondrocytes of mouse
growth plates
To examine the physiological function of FGFR3 in the inhibition of
BMP signaling, we used Fgfr3 knockout (Fgfr3−/−) [6] and ACH mice
(Fgfr3G369C/+; constitutive active FGFR3) [7] we generated previously.
We found that the phosphorylation of Smad1/5/8 (p-Smad1/5/8) in pri-
mary chondrocytes from Fgfr3−/−micewas signiﬁcantly increased com-
pared to the wild-type controls with or without BMP-2 stimulation
(Fig. 3a). The immunohistochemistry analysis also showed that the im-
munoreactivities of BMPR1a and 1b were increased in the primary
chondrocytes of Bmpr1aﬂox/ﬂox;Fgfr3−/− mice compared with that of
Bmpr1aﬂox/ﬂox;Fgfr3+/− mice (Fig. 3b), and the BMPR1a protein could
not be detected in the growth plates of double knockout (Bmpr1a-cKO;
Fgfr3−/−) mice (Fig. 3b). We further observed that depletion of FGFR3
did not affect themRNA level of BMPR1a and 1b (Fig. 3c), which suggests
that the inﬂuence of FGFR3 on BMPR1 is at the post-transcriptional level.sults of pSmad1/5 in the primary chondrocytes from Fgfr3−/− mice and their wild-type
tiﬁed using software ImageJ (version 1.47). The error bars indicate the standard deviation
MPR1a and 1b in the growth plates of Bmpr1aﬂox/ﬂox;Fgfr3−/−, Bmpr1aﬂox/ﬂox;Fgfr3+/− and
c and hypertrophic zones was calculated (n = 3, two-way ANOVA, *p b 0.05, **p b 0.01).
R results of BMPR1a and 1b from primary chondrocytes of 5-day-old Fgfr3−/− and wild-
from 5-day-old ACH mice and their wild-type littermates. e. Quantitative analysis of the
Real-time PCR analysis of total mRNA from primary chondrocytes of 5-day-old ACH and
**p b 0.01, ***p b 0.001).
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BMPR1b and pSmad1/5 were decreased in the primary chondrocytes
from ACH mice where the protein level of FGFR3 was increased and ac-
tive (Fig. 3d,e). Consequently, BMP targeting genes including Id-1, Id-2,Fig. 4. FGFR3 inhibits BMP signaling pathway in tyrosine kinase independent manner. a. Weste
with wild-type FGFR3 or pcDNA3.1-Flag. b. FGFR3 inhibited the BMP-2 stimulated BRE-Luc or G
sentative of three independent experiments (n= 3, two-way ANOVA, ***p b 0.001). c,d. Wild-
constitutive active receptor BMPR1a (Q227D) activated BRE-Luc reporter activity. FGFR3 K5
***p b 0.001). e. PD173074 inhibited reporter gene activity for ERK MAPK, but could not rescu
two-way ANOVA, ***p b 0.001). f. Overexpression of FGFR3 had no signiﬁcant effect on the turn
(pcDNA3.1-myc) were stimulated with BMP-2 (25 ng/ml) for 1 h. Cells were then harvested at
munoblot. g. Forced expression of FGFR3 signiﬁcantly decreased the levels of c-terminal phosp
ulated with BMP-2 (10 ng/ml) for 30 min. Whole-cell lysates were extracted and subjected toId-3 and Ihh were down-regulated in the chondrocytes from ACH mice
(Fig. 3f). All these data suggest that FGFR3 hyper-activation results
in the decreased level of BMPR1 and impaired BMP signaling in
chondrocytes of mouse growth plates.rn blots of pSmad1/5 in different concentrations of BMP-2 treated HepG2 cells transfected
CCG-Luc reporter activity in NIH3T3 cells. Data are shown as means ± SD and are repre-
type human FGFR3 (c) as well as Y373C (c), K650M (c) and K508M (d) mutants inhibited
08M did not activated reporter gene activity for ERK MAPK (n = 3, two-way ANOVA,
e the inhibitory effect of FGFR3 to caBMPR1a activated BRE-Luc reporter activity (n = 3,
over of phosphorylated Smad1/5. HepG2 cells transfectedwithwild-type FGFR3 or control
the indicated time after withdrawal of BMP-2 and total cell extracts were analyzed by im-
horylated Smad1/5. HepG2 cells transfected with wild-type or mutated FGFR3 were stim-
Western blotting for c-terminal phosphorylated Smad1/5.
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It is well documented that FGF/FGFR activated ERK-MAPK induces
degradation of Smad1/5 by phosphorylating its linker region to inhibit
BMP signaling [44]. Our above data showed that hyperactive FGFR3 de-
creased the protein levels of BMPR1s and its downstream signaling cas-
cades in chondrocytes. To dissect the mechanism of FGFR3 inhibiting
BMP signaling, we used another BMP-2-responsive cell lines to examine
whether FGFR3 inﬂuences BMP signaling through its kinase activity. In
this study, HepG2 and NIH3T3 cells were hired as the cell models.
HepG2 is a human liver carcinoma cell line and its BMP-responsive
characteristic is well established. NIH3T3 cell line is isolated from
desegregated NIH Swiss mouse embryonic ﬁbroblasts and has been
proven to be very useful in DNA transfection studies. A Western
blot analysis showed that HepG2 cells, transfected with FGFR3 re-
quired higher concentration of BMP-2 to elicit detectable Smad1/5Fig. 5. FGFR3 enhances the degradation of type I BMP receptors through ubiquitination-depe
BMPR1a in HEK293T cells. Quantitative analysis of HA-BMPR1a band signal intensity was per
b. FGFR3 shortened the half-life of BMPR1a. HEK293T cells transfected with pcDNA3.1 or My
were assayed and quantiﬁed (lower panel). CHX, Cycloheximide. c,d. FGFR3 affected the protei
way. Quantitative analysis of the band signal intensity of HA-BMPR1a and HA-BMPR1b (n =
inactivated FGFR3 decreased luciferase activity induced by HA-caBMPR1a (n = 3, two-way ANphosphorylation after 30 min of treatment (Fig. 4a). Luciferase assays
showed that wild-type FGFR3 signiﬁcantly inhibited BMP-2 induced
BRE-Luc and GCCG-Luc reporter activity in NIH3T3 cells (Fig. 4b). Ex-
pression of two constitutively active FGFR3 (FGFR3-Y373C and FGFR3-
K650M, causing TDI and TDII in humans, respectively) (Fig. 4c) and a
kinase-inactivated FGFR3 (FGFR3-K508M) [49] (Fig. 4d) also impaired
the BMP signaling induced by constitutively active BMPR1a (Q227D)
(HA-caBMPR1a). Furthermore, we found that PD173074, a potent cell-
permeable and ATP-competitive inhibitor of FGFR tyrosine kinase activ-
ity, inhibited the FGFR3-induced ERK luciferase activity effectively
(Fig. 4e), but failed to rescue the inhibitory effect of FGFR3 on the
caBMPR1a-induced Smad-transcriptional activity (Fig. 4e). These re-
sults suggest that the tyrosine kinase activity of FGFR3 is not required
for the inhibition of FGFR3 on BMP signaling.
Due to the importance of both the peak intensity and the turnover of
the phosphorylated proteins during signaling, we considered whetherndent pathway. a. Increasing amounts of wild-type or mutant of FGFR3 affected the HA-
formed. The error bars indicate the standard deviation from three separate experiments.
c-FGFR3 were treated with CHX (50 μg/ml) for the indicated time. The levels of BMPR1a
n level of HA-BMPR1a (c) and HA-BMPR1b (d) through a ubiquitination-dependent path-
3, two-way ANOVA, *p b 0.05). e. MG132 (25 μM) recovered the wild-type or kinase-
OVA, **p b 0.01, ***p b 0.001).
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over of the phosphorylated Smad1/5. HepG2 cells transfected with
FGFR3 or control (pcDNA3.1-myc) were stimulated with BMP-2
(25 ng/ml) for 1 h. Cells were harvested at the indicated times after
withdrawal of BMP-2 and total cell extracts were analyzed. Our results
showed that overexpression of FGFR3 had no signiﬁcant effect on the
turnover of pSmad1/5 after BMP-2 stimulation (Fig. 4f), while FGFR3
signiﬁcantly decreased the levels of phosphorylated Smad1/5 in
HepG2 cells treated with BMP-2 (Fig. 4g, Lanes 7, 8, 9, and 10 vs Lane
6) or vehicle (Fig. 4g, Lanes 2, 3, 4, and 5 vs Lane 1). Overexpression of
FGFR3 signiﬁcantly decreased the BMP-2-induced peak intensity whileFig. 6. FGFR3 prompts BMPR1a degradation through E3 ligase Smurf1. a. FGFR3 enhanced the a
FGFR3-mediated BMPR1a degradation in HepG2 cells. The BMPR1a band signal intensity w
ubiquitination of BMPR1a. In vivo ubiquitination assay was performed in the HEK293T cells
ubiquitinated proteins were precipitated followed by immunoblotting with an anti-HA ant
expressed with Smurf1 (CA), HA-BMPR1b and Myc-FGFR3 for 24 h. The cells were treated w
e. FGF-2 stimulated the association of HA-BMPR1a andMyc-Smurf1. HEK293T cells were co-tra
for 12–16 h and stimulated by FGF-2 (50 ng/ml) for 30 min. Whole-cell lysates were extracted
when FGFR3 was depleted in HeLa cells. The band signal intensity was quantiﬁed (n = 3, Studhad no effect on the turnover of pSmad1/5, suggesting that FGFR3
inhibits BMP-2-induced peak intensity of phosphorylated Smad1/5.
Collectively, FGFR3 inhibits BMP-2- or constitutively activated BMPR1-
induced phosphorylation of Smads through a mechanism independent
of its tyrosine kinase activity.
3.5. FGFR3 enhances the ubiquitination and degradation of
Type I BMP receptors
To explore the mechanism of FGFR3-induced impairment of BMP
signaling, we further analyzed whether FGFR3 affects the protein levelbility of Smurf1 in the degradation of BMPR1a. b. Depletion of Smurf1 by siRNA prevented
as quantitatively analyzed (n = 3, two-way ANOVA, *p b 0.05). c. FGFR3 enhanced the
co-transfected with HA-BMPR1a, His-Myc–ubiquitin, Myc–Smurf1 and Flag-FGFR3. The
ibody. d. FGFR3 enhanced the interaction of BMPR1 and Smurf1. HEK293T cell was co-
ith MG132 (25 μM) for 6 h and coimmunoprecipitation experiments were performed.
nsfectedwith HA-BMPR1a andMyc-Smurf1. After 24 h transfection, the cells were starved
and analyzed as described before. f. The interaction of Smurf1 and BMPR1a was impaired
ent's t-test, *p b 0.05).
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FGFR3 signiﬁcantly reduced the HA-BMPR1a protein level in a dose-
dependent manner in HEK293T cells (Fig. 5a), consistent with the re-
sults from primary chondrocytes of Fgfr3−/− or ACH mice (Fig. 3a–e).
When HA-BMPR1a was co-expressed with Flag-FGFR3 in HEK293T
cells in the presence or absence of the protein synthesis inhibitor cyclo-
heximide (CHX), BMPR1a turnover ratesweremarkedly increased with
expression of FGFR3 (Fig. 5b). Furthermore, MG132, an inhibitor of the
proteasome, partially rescued the protein level of BMPR1a, while a lyso-
somal inhibitor chloroquine failed (Fig. 5c), suggesting that the de-
creased BMPR1a by FGFR3 is through the ubiquitination–degradation
mechanism. In addition, we also observed that FGFR3 enhanced the
degradation of BMPR1b through a ubiquitination–degradation mecha-
nism (Fig. 5d). Consistently, MG132 also recovered the wild-type or
kinase-inactivated FGFR3-reduced luciferase activity induced by HA-
caBMPR1a (Fig. 5e). Our data indicate that FGFR3 boosts the degrada-
tion of type I BMP receptors in an ubiquitination-dependent manner.3.6. FGFR3 promotes degradation of BMPR1a through Smurf1
Smurf1, an E3 ligase, binds Smad1/Smad5 or BMPR1 [31], causing
their ubiquitination and subsequent proteasomal degradation [29,30].
To address themechanism of FGFR3 in the degradation of type I BMP re-
ceptors, we examined whether FGFR3 mediated degradation of BMPR1
through Smurf1. A Western blotting analysis showed that FGFR3
strongly promoted the degradation of BMPR1a in the presence of
Smurf1 (Fig. 6a), whereas knockdownof Smurf1 by an siRNAprevented
FGFR3-mediated BMPR1a degradation in HepG2 cells (Fig. 6b). We fur-
ther demonstrated that FGFR3 enhanced the ubiquitination of BMPR1a
in HEK293T cells (Fig. 6c). We next examined whether FGFR3 enhances
the interaction of BMPR1 and Smurf1. The IP results showed that the in-
teraction between Smurf1 and BMPR1b was enhanced in the presence
of FGFR3 (Fig. 6d). FGF-2 also enhanced the interaction of Smurf1 andFig. 7. BMP-2 rescues the retardation of the embryonic metatarsal growth of the TDII mice
dorsomorphin. b. ATDC5 cells were cultured for 3 days for chondrocyte differentiation in the
was analyzed by Real-time PCR (n= 3, two-way ANOVA, *p b 0.05, **p b 0.01, ***p b 0.001). c.
tarsals from wild-type and TDII mice were treated with BMP-2 (100 ng/ml) for 7 d. The percen
tured bones was measured and calculated (n = 5, two-way ANOVA, *p b 0.05).BMPR1a (Fig. 6e). Conversely, we also found that in HeLa cells, where
the protein levels of FGFR3, BMPR1a and Smurf1 are relatively higher,
the interaction of Smurf1 and BMPR1a was impaired when FGFR3 was
knocked down by an siRNA (Fig. 6f). All these data suggested that
FGFR3 enhances the interaction of Smurf1 and BMPR1 and promotes
the degradation of BMPR1.3.7. BMP-2 rescues the retardation of the embryonic metatarsal growth of
the TDII mice
To investigate whether FGFR3 hyper-activation results in retarda-
tion of bone growth through inhibition of BMPR1-mediated BMP signal-
ing, we analyzed the effect of dorsomorphin, a speciﬁc inhibitor for
BMPR1a and BMPR1b [54], on chondrocyte differentiation. Firstly, we
found that BMP-2 induced the c-terminal and linker region phosphory-
lation of Smad1/5 in a time-dependent manner and dorsomorphin de-
creased the phosphorylation of Smad1/5 in a dose-dependent manner
(Fig. 7a) in ATDC5 cells. Furthermore, the Real-time PCR analysis results
showed that dorsomorphin treatment inhibited the expression of the
early chondrocyte differentiation marker genes Col2 and Sox9, similar
to the effect of FGF-2 on ATDC5 cells (Fig. 7b). To further conﬁrm the
role of BMP signaling in FGFR3-mediated bone growth inhibition, we
sought to rescue the retarded growth of the embryonic metatarsals of
TDII mice with BMP-2. While the metatarsals from the TDII mice
showed retarded bone growth (comparing with that from their wild-
type littermates), addition of BMP-2 signiﬁcantly promoted the growth
of metatarsals (Fig. 7c). Intriguingly, BMP-2 signiﬁcantly promoted the
hypertrophic zone length of embryonic metatarsals, but not the miner-
alized and proliferation zone length (Fig. 7c). These results suggest that
BMP-2 rescued the FGFR3-induced retardation of bone growth mainly
by promoting chondrocyte differentiation. Taken together, FGFR3 in-
hibits the bone growth partially through inhibition of BMP signaling in
chondrocytes.. a. BMPR1 inhibitor inhibits the phosphorylation of Smad1/5 in chondrocytes. DorM,
presence of FGF-2 (25 ng/μl) or dorsomorphin (10 μM). The expression of Col2 and Sox9
BMP-2 ameliorated the cartilage growth retarded by hyper-activation of FGFR3. Themeta-
tage increase in the total, mineralization, hypertrophic and proliferation length of the cul-
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Achondroplasia is caused by gain-of-function mutations of FGFR3,
which inhibits mainly chondrogenesis of endochondral ossiﬁcation
[4,7,24,55]. Although many signaling pathways have been reported in
the regulation of chondrogenesis, it remains unclear how the develop-
ment of chondrogenesis and achondroplasia is regulated coordinately
by diverse signaling pathways. In this study, we revealed that FGFR3
inhibits chondrocyte differentiation through inhibition of BMP sig-
naling. We found that FGFR3 negatively regulates BMP signaling in
chondrocytes by facilitating BMPR1 for degradation.
The crosstalk between FGF and BMP pathways during chondrocyte
development has been investigated in different studies [32,33,40,44,
56,57]. However, since multiple signaling components of FGF and BMP
pathways are expressed in chondrocytes [10,58], it is unclear how the
crosstalk between BMP and FGF signaling regulates chondrogenesis
and development of ACH. Double Bmpr1a and Bmpr1b null mice have a
phenotype of increased expression of FGFR1 in chondrocytes [32], sug-
gesting the potential role of this crosstalk in chondrogenesis. However,
the absence of gross phenotype in chondrogenesis with either gain-of-
function mutation of FGFR1 or chondrocyte-speciﬁc deletion of FGFR1
indicates that FGFR1 is not the primary receptor for the crosstalk be-
tween FGF and BMP signaling during chondrogenesis [59,60]. FGFR3 is
the major receptor in chondrocytes to regulate chondrogenesis [10].
More importantly, both FGFR3 andBMPR1a have relatively higher levels
of expression at the prehypertrophic zone, an area critically controlling
growth plate chondrocyte differentiation [32]. In this study, we found
that chondrocyte-speciﬁc inactivation of Bmpr1a rescued the bone
overgrowth phenotypes in FGFR3 deﬁcient mice by alleviating their
increased differentiation of chondrocytes, and FGFR3 hyper-activation
results in impaired BMP signaling in chondrocytes and the speciﬁc
inhibitor of BMPR1 mimics the effect of hyperactive FGFR3, leading
to the retardation of bone growth. Furthermore, BMP-2 alleviated the
retarded growth of cultured bones from TDII mice by increasing
the chondrocyte differentiation. All these in vitro and in vivo results
showed for the ﬁrst time that direct down-regulation of BMPR1-
mediated BMP signaling plays an important role in the regulation of
chondrogenesis and achondroplasia by FGFR3. We believe that the
counter balance between FGFR3 and BMP signaling pathways plays an
important role in maintaining the normal chondrocyte development.
Imbalance between these two signaling pathways, for example over-
activation of FGFR3, results in developmental abnormalities such as
achondroplasia.
It is well documented that FGF-2, by activating ERK1/2 MAPK path-
way, promotes the phosphorylation of the linker region of Smad1/5/8,
leading to their degradation in chondrocytes and other cells [33,44].
We found that FGFR3 resulted in a decrease of BMPR1 through a
ubiquitin-mediated degradationmechanism. FGFR3 promoted the com-
plex formation of BMPR1/Smurf1, mediating its degradation, which led
to impair the BMP signaling as measured by the phosphorylation of
c-terminal region of Smad1/5. Although FGFR3 induces ERK1/2 phos-
phorylation and further phosphorylates Smad1/5 linker region for the
protein degradation, FGFR3-mediated degradation of membrane
BMPR1 affects the upper stream of BMP signaling, which is a novel
mechanism and likely more important in negative regulation of the
BMP signaling pathway during chondrogenesis.
Modulation of BMP signaling occurs at different levels, including
degradation of BMPR1 [61–63] through an internalization process
(endosome) mediated by caveolin-1 [64]. Smurf1 and Smurf2 were
reported to antagonize the TGF-β/BMP pathway by targeting Smads,
TGF-β/BMP receptors or TGF-β-responsive transcription factors for
ubiquitination-mediated degradation [30,31,65,66]. We showed that
FGFR3 promotes the association between BMPR1 with Smurf1. FGFR3-
mediated degradation of BMPR1 through Smurf1 ubiquitination process
is different from degradation of BMPRs by a caveolin-1-mediated inter-
nalization process [64]. However, the mechanisms by which FGFR3promotes the association between BMPR1 with Smurf1 need more in-
vestigations in the future study.5. Conclusion
In these studies, we propose a novel model that FGFR3 signaling in-
hibits chondrocyte differentiation through down-regulation of BMP sig-
naling by Smurf1-mediated ubiquitination and degradation of BMPR1.
Our study provides novel insights for understanding the mechanisms
of the chondrogenesis and FGFR3-related chondrodysplasia, as well as
the crosstalk between FGF and BMP pathways, two essential signaling
pathways in the development of a variety of organs and diseases.Acknowledgements
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